Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Proto

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
ESMO Open|June 15, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)E G Pizzutilo, A G Agostara, S Oresti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2024
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)C Proto, M Ganzinelli, S Manglaviti, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
ESMO Open|June 15, 2024
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)E G Pizzutilo, A G Agostara, S Oresti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2024
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)C Proto, M Ganzinelli, S Manglaviti, et al.
Pageof 8